A new study on lazy eye found that programmable electronic glasses help improve vision in children just as well as the more traditional treatment using eye patches. This “digital patch” is the first new effective treatment for lazy eye in half a centur…
Medflow announces availability of advanced cloud-based EHR system
Medflow, Inc., the leading electronic health record (EHR) and practice management solutions provider for ophthalmologists, announced today the availability of Medflow 2.0 EHR, its most advanced cloud-based EHR system. Medflow 2.0 EHR streamlines the en…
Uncategorized
Speaker calls for prospective studies of donor diabetes and keratoplasty outcomes
LAS VEGAS — Because the effect of donor diabetes history on keratoplasty outcomes is unknown, there is a need for prospective studies to manage its impact, according to a presentation here. Jonathan Lass, MD, discussed the growing problem of the impact of donor diabetes on the future of the cornea donor pool and patients requiring keratoplasty at the American Academy of Ophthalmology annual meeting.
Ranibizumab Deemed Major Advance for Diabetic Retinopathy
Ranibizumab was noninferior to panretinal photocoagulation for visual acuity in patients with proliferative diabetic retinopathy, according to 2-year results of the Protocol S Study. Medscape Medical News
Uncategorized
Contact lens wearers at greater risk for Acanthamoeba keratitis than non-lens wearers
LAS VEGAS — In patients who are diagnosed with Acanthamoeba keratitis, 85% to 100% are contact lens wearers and 33% are orthokeratology patients, according to a speaker here. “The rates of risk are the same or very similar for hard and soft contact lens wearers. Orthokeratology patients are especially high risk… luckily, if you are a noncontact lens wearer, the risk is fairly low,” Elmer Y. Tu, MD, said at Cornea Subspecialty Day preceding the American Academy of Ophthalmology annual meeting.
Uncategorized
OASIS: Single Jetrea injection results in long-term resolution of vitreomacular adhesion
LAS VEGAS — A single intravitreal injection of 0.125 mg of ocriplasmin can result in long-term resolution of vitreomacular adhesion, according to a presentation here. At the American Academy of Ophthalmology annual meeting, Peter K. Kaiser, MD, presented results from the OASIS study evaluating a single injection of Jetrea (ocriplasmin, Thrombogenics) in patients with vitreomacular adhesion (VMA), including macular hole, and vitreomacular traction (VMT) at 24 months.